ArticleInternational journal of surgery case reports2026
Very rare myoepithelial carcinoma occurred in the humerus: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myoepithelial carcinoma (MEC) most frequently arises in the salivary glands; intraosseous disease is exceptionally rare. Early recognition is challenging, and evidence‑based management is lacking. Case presentation: A 16‑year‑old Japanese male presented with left shoulder pain. A proximal humeral lesion was monitored using radiographs over a 2-year period, after which an urgent biopsy identified MEC. He received two cycles of paclitaxel (200 mg/m Discussion: Despite preoperative and postoperative adjuvant chemotherapy, the patient developed lung metastasis 1 year after surgery and died 6 months later. Delayed biopsy may have contributed to disease progression. Current literature recommends early biopsy, extensive resection, and consideration of molecular targeted therapy. Conclusion: Bone MEC is aggressive; prompt histological diagnosis and multidisciplinary treatment are crucial to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.